| Studies on The Treatment of Myelodysplastic Syndromes by Activating Blood Circulation to Dissipate Blood Stasis PrincipallyDoctoral student Yang Zhenjiang TutorQiu HemingMyelodysplastic Syndromes (MDS) is a series of malignant clonal diseases of hematopoietic stem cell characterized by refractory hematocytopnia and high risk of developing to acute leukemia. Its cause and pathogens is still unclear. There is short of effective therapys clinically, so its prognosis is very bad. Some methods such as differentiation therapy, chemotherapy and bone marrow transplant (BMT) had been used for years, but the results still were unsatisfied.MDS belongs to consumption, hemorrhagic diseases and abdominal mass in traditional Chinese medicine (TCM). Many Chinese doctor treated MDS with invigoration, the effective rate was low. MDS is considered belonging to consumption due to blood stasis, so we mainly use method of activating blood circulation to dissipate blood stasis in treatment of MDS in our hematology department of Guang Zhou university of TCM, and assisted with invigorating Qi, Xue, spleen and kidney. The ricipe named as Yu-Du-Qing(YDQ) was made up.18 cases of MDS treated principally with activating blood circulation to dissipate blood stasis by our department were observed. In courses of treatment patients' clinical syndromes score decreased obviously (p<0.05), patients' living level was improved. It showed that this therapy has better subjective effects. The objective effects were also good, clinical remission rate was 11.11%. Total effective rate was up to 66.67%. The count of white blood cell (WBC), red blood cell (RBC), platelet(PLT)and hemoglobin increased some extently, especially PLT rised significantly(p<0.05), meanwhile blast went down markedly(p<0.05). The dyshemopoiesis also redressed. Long-term effects also let us hearten, the survival stage was long, the longest had been over 66 months, three-year survival rate was 55.56%. Three-year leukemia-evolving rate (16.67%) was low.On the basis of clinical research, the pharmacology effect of YDQ on human erythroleukemia cell line (HEL) was studied with serum-pharmacology methods. The outcome was that the live cell percent, live cell absolute count and optical density (OD) of MTT in three dose group especially the moderate dose group were all lower than those in controlgroup distinctly (p<0.05). The highest cyto-inhibition was 83.99%, cytotoxicity in the moderate group and the high dose group was larger than 20%(30.27% and 32.11% respectively). Flow cytomatry (FCM) examine HEL's DNA content and proliferous cycle showing that DNA content of G, period in high dose group of YDQ was higher than those in control group markedly (p<0.05). It indicated that YDQ could restrain malignant cell growth.Cytomorphology and cytochemistry studies shows that cell in YDQ group was larger than those in control group, that multinuclear cell count rised, that non-specific esterase (AE) was positive and inhibited by NaF, that acid phosphatase (ACP) was positive and inhibited by tartaric acid, that suddan black (SBB), peroxidase (POX) and specific esterase (CE) being specific to granulo-monocyte were negative, these aspects were consistent with character of megakaryocyte. It was proved that YDQ can induce HEL differentiate to megakaryocyte.Apoptosis peak was found in HEL cutured with YDQ moderate dose by FCM, it seems that YDQ can impel HEL apoptosis.Using L,21 j minimal residual disease (MRD) model mice, we observed effects of YDQ in followed aspects: mousy bone marrow nucleating cell, leukemic cell, survival stage and leukemic invading in liver and spleen. Results were that leukemic cell percents in YDQ low dose group and YDQ high dose group were lower than those in control group distinctly (p<0.01), meanwhile normal bone mature cell percents were higher markedly (p<0.05). The degree of leukemic invading in liver and spleen was gentler than that of control group. The mousy survival stage in two experimental group were linger than those in control gr...
|
PDF Full Text Request